My Prostate Cancer has spread to my bones — how is this treated

Treatment for Prostate Cancer That Has Spread to Bones

When prostate cancer spreads to the bones, it's called metastatic prostate cancer (metastatic means the cancer has traveled beyond the original site). This is a serious diagnosis, but there are multiple treatment approaches available. Let me walk you through how doctors typically approach this situation.

How Doctors Think About Bone Metastases

According to the NCCN Guidelines for Advanced-Stage Prostate Cancer, the main treatment for metastatic prostate cancer is androgen deprivation therapy (ADT)—drugs that reduce testosterone levels or block testosterone's effects on cancer cells. Testosterone fuels prostate cancer growth, so lowering it to very low levels (called "castration level") is the foundation of treatment.

However, ADT is rarely used alone anymore. Modern treatment typically combines ADT with one or more additional therapies to be more effective.

Main Treatment Categories for Bone Metastases

1. Hormone Therapy (The Foundation)

• ADT (Androgen Deprivation Therapy): Drugs like LHRH agonists or LHRH antagonists that lower testosterone
• Second-line hormone therapies: Abiraterone (Zytiga), enzalutamide (Xtandi), apalutamide (ARN-509), or darolutamide—these block how cancer cells use remaining androgens (male hormones)

2. Chemotherapy

• Docetaxel is often combined with ADT for newly diagnosed metastatic disease
• Cabazitaxel may be used if the cancer becomes resistant to other treatments

3. Radiopharmaceuticals (Targeted Radiation)

These are specialized drugs that deliver radiation directly to cancer cells:

• Radium-223 (Xofigo): According to NCCN Guidelines, this is specifically used when prostate cancer has spread mainly to bones but NOT to internal organs. It's given as monthly injections for 6 months and works by collecting in bone tissue and releasing radiation that kills cancer cells there. It's often combined with bone-targeted therapy (see below).

• Lutetium-177 (Pluvicto): A newer radiopharmaceutical that targets PSMA (a protein on prostate cancer cells). According to the guidelines, this is typically used after other hormone therapies and chemotherapy have been tried. You'll need a PSMA-PET scan first to confirm this treatment will work for you.

4. Bone-Targeted Therapies (Supportive Care)

These help prevent fractures and reduce bone pain:

• Denosumab (Prolia, Xgeva) or zoledronic acid (Zometa)—these slow bone breakdown and help maintain bone strength
• Often given alongside other treatments

5. Targeted Therapies for Specific Mutations

If genetic testing shows you have a BRCA1 or BRCA2 mutation (about 1 in 4 patients with advanced prostate cancer), you may be eligible for:

• PARP inhibitors like olaparib (Lynparza), rucaparib (Rubraca), niraparib (Akeega), or talazoparib (Talzenna)
• These drugs block DNA repair in cancer cells, causing them to die

6. Radiation Therapy

• External beam radiation therapy (EBRT) or stereotactic body radiation (SABR) can target painful bone tumors directly
• Palliative radiation specifically aims to reduce pain and improve quality of life

7. Immunotherapy

• Sipuleucel-T (Provenge) or checkpoint inhibitors like pembrolizumab (Keytruda) may be options depending on your specific situation

What Happens in Practice: Treatment Combinations

According to NCCN Guidelines and expert sources, modern treatment often involves:

• Doublet therapy: ADT + one additional therapy (like chemotherapy or a second hormone therapy)
• Triplet therapy: ADT + two additional therapies (for patients with high disease burden)

The specific combination depends on:

• How much cancer you have (disease burden)
• Whether your cancer is still responding to hormone therapy
• Your overall health and ability to tolerate side effects
• Genetic testing results
• Your treatment goals

Important Monitoring

After starting treatment, you'll have regular follow-up visits including:

• PSA blood tests every 3-6 months
• Imaging scans as needed
• Physical exams to assess side effects

If your cancer grows or spreads despite treatment, your team may switch to a different therapy. Many patients with advanced prostate cancer eventually receive 2-3 or more different treatments over time.

Questions to Ask Your Oncology Team

1. What is my disease burden? (How much cancer do I have, and where exactly is it?)
2. What genetic testing do you recommend? (This could identify BRCA mutations or other actionable mutations)
3. What is the recommended first-line treatment for my specific situation? (ADT alone, or combination therapy?)
4. Should I have a PSMA-PET scan? (This helps determine if radiopharmaceuticals like Pluvicto might work for me)
5. What bone-targeted therapy do you recommend to prevent fractures?
6. What are the side effects of my recommended treatment, and how will we manage them?
7. Are there clinical trials I should consider?
8. How will we monitor whether treatment is working?

Key Takeaway

Bone metastases from prostate cancer are treated with a combination approach—usually hormone therapy as the foundation, combined with chemotherapy, targeted therapies, radiopharmaceuticals, or radiation depending on your specific situation. The goal is to slow cancer growth, reduce symptoms, maintain quality of life, and extend survival.

According to the NCCN Guidelines, treatment intensification (using multiple therapies together) is now standard of care for metastatic prostate cancer, rather than single-agent therapy alone.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.